- Patients with advanced lung cancer and cough who received aprepitant plus a cough suppressant reported significantly greater cough relief than those treated with cough suppressant alone.
Why this matters
- Cough is common in patients with lung cancer, but as the American College of Chest Physicians has noted, evidence to guide treatment is lacking.
- Randomized controlled trial.
- 128 patients with advanced lung cancer and cough that had persisted for >2 weeks despite use of cough suppressant received either aprepitant plus physician’s choice of cough suppressant (n=64) or physician’s choice of cough medication alone (n=64) for 7 days.
- Funding: Tata Memorial Center Research Administration Council; others.
- Mean visual analog scale scores decreased significantly more from baseline to 9 days after treatment initiation with aprepitant+suppressant:
- From 67.68 to 38.5 mm with aprepitant+suppressant vs from 62.2 to 48.57 mm with suppressant only (P<.001>
- Mean Manchester Cough in Lung Cancer Scale scores decreased significantly more from baseline to 9 days after treatment initiation with aprepitant+suppressant:
- From 33.06 to 25.17 with the combination vs from 29.64 to 23 with suppressant only (P<.001>
- The aprepitant group also had a significant improvement in cough-specific QoL questions (P=.017).
- No significant difference between groups in adverse events.
- Single-center study with no placebo group.